Skip to main content
KAZIA THERAPEUTICS LTD logo

KAZIA THERAPEUTICS LTD — Investor Relations & Filings

Ticker · KZIA ISIN · US48669G1058 US Professional, scientific and technical activities
Open in API
Filings indexed 1,045 across all filing types
Latest filing 2025-09-11 Regulatory Filings
Country US United States of America
Listing US KZIA

About KAZIA THERAPEUTICS LTD

https://www.kaziatherapeutics.com/

Kazia Therapeutics Ltd. is an oncology-focused biotechnology company engaged in the development of innovative drugs for cancer. The company's lead program is paxalisib, a small molecule inhibitor of the PI3K/AKT/mTOR pathway designed to cross the blood-brain barrier, which is being investigated for various forms of brain cancer. Its development pipeline also includes EVT801, a selective VEGFR3 inhibitor being studied for its potential to block the growth of blood and lymphatic vessels that support tumor growth. The company focuses on addressing cancers with high unmet medical needs through its portfolio of targeted therapies.

Recent filings

Filing Released Lang Actions
6-K
Regulatory Filings Classification · 95% confidence The document is a Form 6-K filed with the SEC by a foreign private issuer, Kazia Therapeutics Limited. It reports the issuance of a press release dated September 11, 2025, regarding clinical results. The document is short (2126 characters) and primarily serves to announce and incorporate by reference the press release. There is no substantive financial data or detailed report content within this filing itself. According to the 'MENU VS MEAL' rule, such a filing that announces or attaches a press release without containing the full report or financial data should be classified as a Regulatory Filing (RNS).
2025-09-11 English
Regulatory Filings 2025
Regulatory Filings
2025-08-14 English
Major Shareholding Notification 2025
Major Shareholding Notification
2025-08-05 English
424B3
Capital/Financing Update Classification · 100% confidence The document is a Form 6-K filed pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 by Kazia Therapeutics Limited, a foreign private issuer. It contains detailed information about a private placement of equity securities, including the terms of the securities purchase agreement, pre-funded warrants, and related exhibits. The document includes legal and financial details about the private placement transaction and the securities involved. It is not an annual report, earnings release, or management discussion, but rather an update on a capital raising event. The presence of a securities purchase agreement and detailed terms of the private placement clearly indicate this is a Capital/Financing Update filing. The document length is substantial and contains substantive information about the financing transaction, not merely an announcement or a brief summary. Therefore, the appropriate classification is Capital/Financing Update (CAP).
2025-08-01 English
424B3
Capital/Financing Update Classification · 100% confidence The document is a Form 6-K filed by Kazia Therapeutics Limited, which is a report of a foreign private issuer pursuant to the Securities Exchange Act of 1934. The content details a private placement of equity securities, including ordinary shares and pre-funded warrants, with terms and conditions of the purchase agreement and warrants. It includes exhibits such as the form of the purchase agreement and the pre-funded warrant, and a press release announcing the private placement. The document is not an annual or interim financial report, audit report, earnings release, or any other financial statement. It is a regulatory filing reporting a capital raising event and related agreements. The document is lengthy (15,000 characters) and contains substantive information about the private placement transaction. Therefore, the most appropriate classification is Capital/Financing Update (CAP).
2025-08-01 English
424B3
Capital/Financing Update Classification · 95% confidence The document is a Form 6-K filed by Kazia Therapeutics Limited, which is a report of a foreign private issuer pursuant to SEC rules. It details a private placement of equity securities, including ordinary shares and pre-funded warrants, with terms and conditions of the securities purchase agreement and warrants. The document includes exhibits such as the form of the purchase agreement and the pre-funded warrant, and a press release announcing the private placement. The document is not an annual or interim financial report, nor an earnings release, audit report, or management discussion. It is a regulatory filing reporting a capital raising transaction and related agreements. The document is substantive and detailed, not merely an announcement or a certification. Therefore, the most appropriate classification is Capital/Financing Update (CAP).
2025-08-01 English

Browse filings by year

23 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.